attention, this article evaluates the costs of specific drugs and their sequential use in the lower-risk IPSS (low and intermediate-1) subgroups based on the NCCN guidelines. Results estimate an average annual cost for potentially anemia-altering drugs of $63,577 per patient, ranging from $26,000 to $95,000, depending on the specific therapies. In patients for whom the therapies fail, annual costs for iron chelation plus red blood cell transfusions are estimated to average $41,412. The economic impact of drug therapy should be weighed against the patient's potential for improvement in clinical outcomes, quality of life, and transfusion requirements. (JNCCN 2008;6:942-953) 
Myelodysplastic syndromes (MDS) are a group of myeloid clonal hemopathies with morbidities related to their 2 major clinical characteristics: clinically significant cytopenias and propensity to progress into a form of acute myeloid leukemia (AML). 1 Because these features are heterogeneous within MDS, patients have been categorized into prognostic subgroups. A major approach to this categorization is the International Prognostic Scoring System (IPSS) for MDS, which incorporates the patient's marrow blast percentage, cytogenetics, and number of cytopenias. 2 The NCCN Myelodysplastic Syndromes Guidelines Panel recommends using the IPSS, patient age, and performance status to aid therapeutic management approaches. 3, 4 Treatment recommendations for patients in the lower-risk IPSS categories (low and intermediate [INT] -1) are predominantly aimed at hematologic improvement, particularly correction of anemia, whereas treatment for patients in higher-risk IPSS groups (INT-2 and high) is directed at altering disease natural history.
Erythropoietic stimulating agents (ESAs), including recombinant erythropoietin alfa and darbepoetin alfa, have been the mainstay of therapy for anemia associated with MDS. [5] [6] [7] [8] [9] [10] [11] [12] Data supporting the clinical efficacy of 4 drugs have led to recent FDA approval for their use in MDS: azacytidine and decitabine for all stages of disease, 13, 14 lenalidomide for low-risk anemic patients with del(5q) chromosomal abnormality, 15 and deferasirox for treatment of iron overload. 16 Deferasirox has been shown to have comparable efficacy in iron chelation to the prior standard chelation drug, deferrioxamine. 17, 18 However, because it is an oral agent, deferasirox has advantages compared with deferrioxamine, which requires prolonged subcutaneous administration. An alternative regimen for decitabine treatment has been useful in permitting outpatient administration. 19 Lenalidomide has also been shown to improve hemoglobin levels in lower-risk patients with MDS lacking the del(5q) chromosomal abnormality, albeit with a lower response rate compared with those who have del(5q). 20 In addition, data have indicated that immunosuppressive therapy using agents such as antithymocyte globulin and cyclosporine is beneficial in a subset of patients with MDS. 21 In a variable proportion of patients, these treatments have shown clinical benefit, including hematologic improvement, improved quality of life, delayed transformation to AML, and prolonged survival with some agents. In addition, the important decrease in need for red blood cell (RBC) transfusions occurred concomitant with improved hemoglobin levels in initially anemic individuals who showed effective clinical response with drug therapy. [22] [23] [24] The development of novel therapeutic agents for MDS has substantially impacted the financial costs of treatment for these patients.
Health care costs in the United States have risen dramatically over the past several decades, now exceeding $2 trillion annually, or approximately 16% of the gross domestic product. 25 U.S. health care spending in 2006 increased another 6.7%, with prescription drug spending rising 8.5%. 25 The costs of cancer care represent approximately 10% of the gross domestic product, or roughly $200 billion, of which approximately 40% are direct medical expenditures. [26] [27] [28] Although the economic impact of cancer and its hematologic complications have received considerable attention, [29] [30] [31] [32] [33] the expenditure related to MDS, its treatment, and associated complications has received only limited attention.
Some studies have begun addressing the individual costs of drugs used in selected patients with MDS. 10, 34 These reports have limited their focus to only a few therapeutic options used for patient management. No studies have yet addressed the costs of drugs associated with overall management of patients with MDS according to the global clinical practice guidelines developed for treating the disease. Most patients with MDS have anemia at presentation, and many require RBC transfusions and management of transfusion-related complications. 10 Several investigators have estimated the total costs associated with RBC transfusions. 18, 22, 24, 35 To more fully evaluate drug costs associated with the current management of MDS, this study adhered to the recommended approach of the NCCN guidelines, based on relevant treatment for lower-risk (IPSS low/INT-1) patients for 1 year. The authors compared the economic impact of differing therapeutic options (drug use) and evaluated the costs for individual drugs. The proportion of patients in each therapeutic category and those anticipated to experience response to specific drugs was estimated based on published literature. For comparative purposes, the authors also included the costs of RBC transfusions (with or without drugs used for iron chelation). These data should provide a useful resource for cost analyses of drugs used to treat MDS.
Methods
For unit costs of the drugs, the authors used standard evaluation procedures, including use of the Medicare Part B reimbursement schedule and Medicare 2007 Hospital Outpatient Prospective Payment System for infusions, 36 because most patients with MDS are elderly (median age, approximately 68 years).
1,2 The authors used NCCN recommended drugs, doses, and duration of treatment for responders and nonresponders, transitioning to second-and third-line therapy as recommended. 3, 4 The economic analysis presented herein is based on a clinical decision model evaluating economic outcomes (annual drug costs for the initial treatment year) associated with the management of lower-risk (IPSS low/INT-1) patients with MDS and clinically significant cytopenias treated according to the updated NCCN Clinical Practice Guidelines in Oncology: Myelodysplastic Syndromes (Version 1, 2009). 4 Major management pathways considered in this analysis, as in the guidelines, are for 1) patients with documented del(5q) with or without other cytogenetic abnormalities, 2) patients without del(5q) but with symptomatic anemia, and 3) patients without del(5q) or symptomatic anemia but with thrombocytopenia or neutropenia.
Management of patients with symptomatic anemia is further stratified based on likely responsiveness to an ESA, the patient's serum erythropoietin level of either less than or equal to 500 mU/mL or greater than 500 mU/mL, and the presence or absence of ring sideroblasts ( Figure 1 ). Baseline cost assumptions are shown in Table 1 . Within each group, the model estimates drug treatment costs based on currently recommended therapies, including relevant doses and likely duration of treatments (Tables 1 and 2 ). The model incorporates the likelihood of patients being within specific treatment groups and the probabilities of treatment response and nonresponse from evidence-based review of current literature (Table 3) . Erythroid hematologic responses were generally considered to be those rendering patients RBC transfusion-independent.
Cost Estimates
Costs are estimated for the first year of NCCN guideline-directed therapy. Drug treatment costs were estimated from a third-party payer perspective, based on widely accepted estimates of reimbursement rates from the Centers for Medicare and Medicaid Services or publicly available third-party payer sources. [36] [37] [38] Other treatment-related direct and indirect costs were not considered, such as costs of testing, patient transportation, and complications. Costs were measured in U.S. dollars using the most recent data available. For most injectable agents, unit costs were obtained from the Medicare Part B reimbursement schedule from October 2007. 38 The cost estimates for oral lenalidomide and deferasirox were based on 85% of the average wholesale price because of the generally accepted use of this methodology adopted by Medicare in the design of the Part D Program. 37 The cost estimate for deferoxamine was based on Medicare reimbursement limits published by a major third-party payer (Cigna Health Services). 36 Costs for the key components of RBC transfusions were based on the Medicare Hospital Outpatient Payment System. 38 Annual composite treatment costs for patients were generated by a model based on the patient's expected treatment regimen according to the recommended NCCN pathway for their clinical subtype Annual costs were based on patients being treated for 12 mo (i.e., patients would be considered to have responded to the specified treatment). **Costs for oral lenalidomide and deferasirox were based on the average wholesale price x 85%. † † Drug given daily. ‡ ‡ Drug given 21 d/mo. § § Costs for a 4-d hospitalization must be added, because ATG is generally administered in hospital. ¶ ¶ Costs for deferoxamine were based on Medicare rates of average sale price + 6%. ***Based on patients receiving the subcutaneous infusions 6 d/wk.
(indicated in Figure 1 ), estimated probability of response (defined by the cited literature), and costs of the respective drug regimens. Costs for each drug and usage pathway for treatment were analyzed. Dosage regimens, baseline unit costs, and estimated monthly and annualized reimbursements are presented in Table  1 . Costs not considered include additional direct costs associated with drug administration, professional fees, laboratory testing, and treatment complications, along with indirect costs, such as transportation, loss of productivity, and patient out-of-pocket expenses.
In situations where alternate drugs could be used (e.g., epoetin alfa vs. darbepoetin alfa, azacitidine vs. decitabine, deferasirox vs. deferroxamine), an estimate of the average monthly cost was also created based on the authors' estimate of the likely proportional use of each agent. For instance, costs for iron chelation therapy were estimated to be split for the MDS population, with 90% of patients receiving oral deferasirox and 10% deferoxamine. Table 1 summarizes the differing monthly and annual costs for each drug. Table 2 shows the annual costs for each drug and drug regimen when following the recommended NCCN therapeutic pathways (Figure 1 ). This analysis included costs for patients who experienced response to first-line therapy and those requiring second-or third-line therapy because of lack of therapeutic response to initial or subsequent regimens (Table 2 ). In addition to evaluating costs for drugs used to improve cytopenias in patients with MDS, we also analyzed costs for drugs used for iron chelation therapy and RBC transfusions.
Results
Costs of individual drug treatment regimens based on the updated NCCN guidelines for IPSS patients with low-and INT-1-risk MDS were assessed within the therapeutic pathways depicted in Figure 1 . For pathway 1, the cost of lenalidomide in anemic patients with del(5q) with or without other cytogenetic abnormalities was evaluated using the latest available cost estimates based on either a daily regimen of 10 mg or this dose for 21 days per month (because both regimens are being used). The estimated costs of lenalidomide in patients who experience response to therapy and remain on treatment for 12 months average $5517 per month for the 21-day-per-month regimen and $7882 per month for the daily regimen, for total annual Figure 1 ) and specific references. † Annual costs are based on patients undergoing treatment for a 12 mo period. The patients receiving the cytopeniaaltering drugs for 12 mo would be those considered to have experienced initial response to the specified treatment. ‡ The numbers following the listed drugs represent the months of therapy. In certain sequential regimens, some drugs will be given for 12 mo, whereas others for a lesser period for the same patient (e.g., Epo or Darb12 + G-CSF10). § Based on Epo doses of 60,000-120,000 U/wk. ¶ Based on darbepoetin doses of 300-500 mcg/wk. **Based on G-CSF doses of 120-180 mcg/wk . † † Based on daily lenalidomide dosing for 21 or 30 d/mo and averaged costs for Epo + hypomethylating agents. ‡ ‡ Costs for a 4-d hospitalization must be added, because ATG is generally administered in hospital. § § These will be in addition to those for the drugs initially used to attempt to improve the patient's anemia.
treatment costs of $66,204 and $94,584, respectively. After 4 months of therapy, approximately 30% of patients with del(5q) who are eligible to receive lenalidomide will probably not experience response to continued treatment and will be offered other treatment options based on current NCCN guidelines. Overall, the estimated average costs of treating these patients would be $56,646 to $66,104, representing 4 months of lenalidomide therapy followed by the guideline treatment options (with ESAs; Table 2 ). These estimates do not include the additional costs for potentially needed RBC transfusions and iron chelation. Costs for the remaining relevant drug regimens were also analyzed for pathways 2 and 3, involving treatment of MDS patients without del(5q) but with symptomatic anemia and those without del(5q) or symptomatic anemia but with thrombocytopenia or neutropenia, respectively. The estimated average monthly cost of epoetin and darbepoetin ranged from $2172 to $4348 and $3492 to $7275, respectively, based on the dosage ranges, as described in Tables 1 and 2 . The average costs of hypomethylating agents (azacytidine or decitabine) were estimated to be $4611 and $6180 per course, respectively (for total annual costs of $55,332 and $74,160, respectively), based on the recommended dosing regimens (including a cost estimate for the infusion of decitabine). The average cost of immunosuppressive therapy was estimated to be $18,186 for 6 months of therapy (4 days of equine antithymocyte globulin plus 6 months of cyclosporine; Table 1 ).
Although these costs were for individual drugs (when used alone for 1 year in patients experiencing treatment response), Table 2 also presents the estimated average costs for the drugs when used in the sequence recommended by the NCCN guidelines, including those for patients experiencing response to first-line therapy and those who do not (i.e., no effective erythroid responses).
Composite treatment costs for IPSS low-and INT-1-risk patients were then generated by a model based on the expected treatment regimens according to the recommended NCCN therapeutic pathway for each clinical subtype (indicated in Figure 1 ), estimating the probability of response and costs of the respective drug regimens. Details of the clinical decision model are shown in Figure 2 . Annual cost for treating the patients with non-del(5q) experiencing symptomatic anemia (approximately 83% of patients) was estimated to be $63,112 (Table 3 ). Cost for sequentially treating patients with del(5q) (approximately 10% of the patients) was estimated to be $86,799. Cost for the remainder of the low-and INT-1-risk patients (i.e., those with symptomatic thrombocytopenia or neutropenia; approximately 7%) was estimated to be $35,921. Thus, the estimated annual cost for patients within the IPSS low-and INT-1-risk categories, derived by the weighted mean of the product of $86,799 times 10% plus $63,112 multiplied by 83% plus $35,921 multiplied by 7%, yielded an overall estimated average of $63,577. 4 Costs do not incorporate those for RBC transfusions or iron chelation therapy, which are included in Tables 1 and 2 and text. ‡ Patients with ≥ 15% ring sideroblasts.
The composite cost estimate of $63,112 for patients with non-del(5q) MDS who had symptomatic anemia was derived from a series of cascading decision branches, each with its own associated costs. Cost estimates were generated by multiplying the individual or unit costs by the likelihood (based on probabilities defined by the cited literature) for each branch to occur. For example, patients with symptomatic anemia were divided into 3 subgroups: 1) those with fewer than 15% ringed sideroblasts and serum erythropoietin of 500 mU/mL or less (~72% of patients); 2) those with 15% or more ringed sideroblasts and serum erythropoietin of 500 mU/mL or less (~13%); and 3) those with serum erythropoietin greater than 500 mU/mL (~15%). The estimated costs for each of these subgroups were $61,797, $66,969, and $66,084, respectively, yielding a weighted average of $63,112.
The composite cost estimate of $61,797 for the most frequent subgroup (i.e., patients with < 15% ringed sideroblasts and serum erythropoietin ≤ 500 mU/mL) was derived from the defined treatment options and estimated likelihood of response. Given an approximate 30% probability that these patients would experience an erythroid response, the responders would incur 12 months of costs ($4322 per month; $51,864 total). For patients not experiencing response (70%), granulocyte colony-stimulating factor (G-CSF) was added to therapy. Assuming an observation time of 2 months to evaluate the response to erythropoietin therapy, these patients would incur 12 months of erythropoietin ($4322) plus 10 months of G-CSF ($376 per month, per Table 1 ; proportions of patients and treatments are shown in Figure 2 ).
Of the 70% of patients who did not experience response to initial erythropoietin therapy, 20% were estimated to experience response to the addition of G-CSF. The remaining 80% for whom both erythropoietin and subsequent G-CSF therapy failed, would require treatment with azacytidine, decitabine, or lenalidomide. Per NCCN guidelines, within the year these patients will have already incurred 4 months of erythropoietin therapy, plus 2 months of G-CSF therapy, plus 8 months of azacytidine, decitabine, or lenalidomide. Of these patients, 25% were estimated to experience response to this third-line of treatment. The remaining 75% of patients not experiencing response to azacytidine, decitabine, or lenalidomide could then be treated with an alternate therapy among 1 of the 3 agents. An additional 25% of these patients are estimated to respond to this treatment step. These patients would then have incurred 4 months of erythropoietin plus 2 months of G-CSF, plus 4 months of azacytidine, decitabine, or lenalidomide, and then 4 months of the alternate therapy among these drugs. Thus, these patients would have incurred composite annual costs of $71,148. The patients who experienced no response would also require standard supportive care (RBC transfusions and iron chelation), with their attendant costs.
These cost estimates for potentially cytopenia-altering drug therapies did not include those for RBC transfusions and iron chelation. Approximately 35% of MDS patients have been reported to require RBC transfusion support. 39 Based on the cited literature, we estimated RBC transfusion costs at $585 per month, assuming 2 units of RBCs per month, including typing and crossmatching. These costs did not include complex evaluations or complications of the transfusion administration.
Iron chelation therapy is commonly recommended for patients with RBC transfusion dependence. NCCN guidelines recommend iron chelation therapy for lower-risk MDS patients who have received or are anticipated to receive 20 to 40 units of RBCs with serum ferritin levels of more than 2500 ng/mL. Two therapies are currently commercially available for iron chelation in the United States: deferasirox orally and deferoxamine subcutaneously. Deferasirox therapy is estimated to cost $3834 per month for a standard regimen of 20 mg/kg per day (Tables 1 and 2 ). The average cost of deferoxamine, 2000 mg/d, administered 6 days per week through subcutaneous infusion is estimated at $1754 per month (Tables 1 and 2) .
Combining the costs of iron chelation therapy using either deferasirox or deferoxamine with those of RBC transfusions, the estimated total cost of this aspect of supportive care would be $4419 or $2339 per month, respectively ($53,028 or $28,068 per year, respectively). The weighted average costs based on likely use (90% deferasirox) would therefore be $3451 per month ($41,412 per year). These costs are additive to those for drugs used to attempt to correct anemia. Thus, considering the weighted average costs for cytopeniaaltering drugs is approximately $63,577, the total drug costs for patients also needing this supportive care would be approximately $104,989 annually. The proportions of patients with IPSS low-and INT-1-risk MDS who are likely to require and experience response The major management pathways considered are for 1) patients with documented del(5q) with or without other cytogenetic abnormalities, 2) MDS patients without del(5q) but with symptomatic anemia, and 3) patients without del(5q) or symptomatic anemia but with thrombocytopenia or neutropenia. Management of patients with symptomatic anemia are then further stratified based on likely responsiveness to an erythropoietic stimulating agent, based on the patient's serum erythropoietin level ≤ 500 mU/mL or > 500 mU/mL and the presence or absence of ring sideroblasts (Figure 1) . to specific drug treatment regimens are indicated in Table 4 .
Discussion
Clinical practice guidelines are generally based on a thorough review and understanding of available evidence for clinical efficacy and safety as assessed by experts in a particular field. Economic considerations for these therapeutic recommendations have generally not been considered and remain in the background of such deliberations. Although the recently updated NCCN Myelodysplastic Syndromes Guidelines are largely based on studies showing the efficacy of new agents, such as hypomethylating agents, lenalidomide, immunosuppressive agents, and the hematopoietic growth factors, each treatment also has direct and indirect cost implications for patients, payors, and society. 40 Treatment and supportive care options have their own impact on disease course, symptoms, and costs. 23, 30, 33, 34, [41] [42] [43] [44] [45] For instance, RBC transfusions have not only recognized risks but also cost implications related to the actual transfusion, management of acute reactions, and long-term economic consequences, such as iron overload requiring iron chelation therapy. [22] [23] [24] Because the drugs discussed herein, which possess unique and specific functions (specialty drugs), are predominantly used to treat patients with IPSS lowand INT-1-risk MDS with clinically significant cytopenias, and NCCN treatment recommendations have been specifically provided for these individuals, we focused our analysis of drug costs on this patient group. Although this evaluation is limited to estimated direct medical costs for drugs used to treat MDS from a payor or institutional perspective, additional costs are, nevertheless, substantive for the patient and family. 40 In addition to the direct costs of delivering medical care, other costs include nonmedical costs incurred while receiving care, such as transportation or family care expenses and indirect costs associated with the morbidity of care (e.g., days lost from work for patient or caregiver). Recent studies in cancer populations suggest that nonmedical costs, including patient time costs, approach as much as half again the direct medical costs during the terminal phase of illness, with hospitalization representing the single largest contribution. 40, 45 In addition, recently reported shifting of cost burdens (i.e., patient copayments) for some costly drugs from insurance companies to patients and their families 46 further increases patient expenses and the potentially severe economic impact of MDS and its treatment. Thus, the need to use these agents in the most rational and cost-effective manner and to control their price is becoming even more germane.
This study, extrapolating empirical data from various sources, evaluated the annual economic impact on MDS patients within the IPSS low-and INT-1-risk subgroups treated according to NCCN guidelines. The model used is based on point estimates of response probabilities to various therapies for the recommended treatment pathways during the initial year of therapy. After unit costs were obtained, the costs for each drug were based on recommended dosing regimens. These data approximate the drug costs based on suggested treatment recommendations, although the study could also benefit from cost estimates based on actual patient experiences. Not considered in this analysis are decrements in dosing caused by drug toxicity or its financial impact (e.g., adverse events, hospitalization costs), as was previously reported in a study assessing costs of a single drug used to treat MDS. 34 The costs associated with treating serious chronic diseases should consider the costs of both drug treatment and managing disease progression or recurrence, and those for treating or preventing treatment-related toxicity. However, given the variability and complexity of these events, this
The model incorporates the likelihood of patients being within specific treatment groups and the probabilities of treatment response and nonresponse from evidence-based review of current literature (Table 3) . (For clarity, this model does not incorporate branches for lenalidomide nonresponders, who would follow the relevant pathway [#2].) Erythroid hematologic responses were generally considered to be those rendering patients red blood cell (RBC) transfusion-independent. The notations to the right of the pathway branches indicate the duration of specific therapy, considering the patients to experience continuous response, response and then treatment failure, or treatment failure. The percent (%) notations indicate the proportion of patients at each step of the pathway. For example, the third treatment branch from the top, cEPO_DARB_MON*12+cGCSF_MON*10, denotes initial treatment with either epoetin or darbepoetin alone for 2 months (to which the patient experienced no response) followed by this treatment combined with granulocyte colony-stimulating factor (G-CSF) for an additional 10 months (thus, 12 months total treatment for epoetin or darbepoetin and 10 months for G-CSF). The estimated proportion of patients in this pathway branch would be 83% X 0.72 X 0.70 X 0.20 = 8.4% (see Table 4 ). The estimated costs for each pathway and their branches are provided in Tables 2 and 3 . The branches indicating "Non-responder (requires RBC transfusions & iron chelation)" denote the need for these patients to receive this supportive treatment in addition to the prior drug therapy they had been scheduled to receive. Costs for iron chelation are provided in Tables 1 and 2 and are stated in the text for RBC transfusions.
continued from previous page information is beyond the scope of this paper and was not incorporated into the analyses. Research involving patients' experience (e.g., from medical claims or registry) would provide important additional information.
The data we obtained indicate that annual costs for potentially cytopenia-altering drug therapy ranged between $26,000 and $95,000 for specific drugs (Tables 1 and 2 ) or between $35,000 and $87,000 for specific treatment pathways, based on the patient's clinical features (Table 3) . Additionally, costs for supportive care (RBC transfusions and iron chelation) were approximately $41,000 (Tables 1 and 2 and text). Figure 1 ) and specific references. † Proportions (%) of patients in each category are based on subgroup incidence and response probability data from the literature. Numbers are rounded off to the nearest integer. See text and specific references. ‡ Proportions (%) of patients likely to be responders to the specified treatment for either 1 y (those responding to first-line therapy) or require the sequential treatments for such response over the year. These proportions are based on data from the literature. See text and specific references. § Total proportions (%) of patients likely to remain in this treatment category for 1 y (product of footnotes b x c). ¶ The numbers following the listed drugs represent the months of therapy. In certain sequential regimens, some drugs will be given for 12 mo, whereas others for a shorter period for the same patient (e.g., Epo or Darb12 + G-CSF10). **Lenalidomide treatment of patients with del(5q).
NCCN guidelines recommend that iron chelation be considered for patients with lower-risk MDS who received 20 to 30 RBC units. However, no data in MDS yet indicate clinical benefit of this approach (in contrast to beneficial data for patients with thalassemia major). Table 4 provides information on the proportions of patients with low-and INT-1-risk MDS likely to undergo the distinct treatment regimens, providing a basis for estimating the total societal costs for treating this subgroup of patients (whereas Tables 1 and 2 indicate the costs for individual patients). Although not specifically modeled, these costs would persist thereafter for patients whose responses continued.
Rather than cost, efficacy and safety remain the major focus of FDA review and approval of new agents; drug costs are mentioned only for informational purposes in clinical practice guidelines such as those from NCCN. However, the major economic impact of these drugs is clearly substantial for patients and society and requires evaluation in the context of a patient's potential for clinical improvement. Given the data from this study, all stakeholders must consider current approaches for optimal determination of drug costs for patients with MDS. To this end, forums discussing these issues from disparate perspectives are warranted and should be valuable.
